FDA Panel Recommends Ban on Popular Painkiller

An advisory panel has recommended that the FDA place a ban on the painkiller Darvon, one of the most widely prescribed opioid painkillers in the US for at least half a century. The ban would include generic propoxyphene (the active narcotic), as well as the brand-name drugs Darvon and Darvocet. The reason? Studies seem to indicate that the drug is no better than aspirin at controlling pain yet carries with it an excessive potential for abuse, addiction, overdose, and suicide.



Narcotic painkillers like propoxyphene fall into three broad classes:



NATURAL opiates: These drugs are derived directly from the opium poppy, like codeine and morphine. Morphine has been something of the gold standard among painkillers for a century.



SEMI-SYNTHETIC opioids: These drugs are derivatives based on the natural opiates and include hydrocodone (Vicodin, Lortab) and oxycodone (Percocet, Percodan, Oxycontin), among many others.



FULLY SYNTHETIC opioids: These drugs are pharmacologically divorced from the natural opium poppy and here’s where you find propoxyphene (Darvon, Darvocet) as well as methadone (Methadose), among others.



Among the benefits of a fully synthetic opioid is the fact that some patients don’t tolerate codeine and codeine derivatives—they’re allergic, for instance—meaning narcotic pain control has to come from one of these, if it comes from anywhere.



Opioid addiction is a very real possibility from any one of these drugs in any of the classes listed. Consequently, for chronic pain patients, the addiction factor is a double scourge: a scourge in that it discourages some doctors from adequately treating pain lest they create dependency in their patients, and a scourge in that they may truly develop a dependency. Either way, the patient loses.



Pain management is a legitimate branch of medicine. Hundreds of thousands of people rely on propoxyphene products to manage their pain. Should the ban take place, other options remain available, but not all of them are going to be any more or less attractive to government policy makers or consumer watchdog groups for the same reasons they don't like propoxyphene.



At any rate, the FDA isn't required to follow the panel's advice but should they do so, patients or their caregivers should consult with their doctor about other viable options for the management of their chronic pain.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap